Stocklytics Platform
Asset logo for symbol RLAY
Relay Therapeutics
RLAY53
$4.23arrow_drop_down2.41%-$0.10
Penny Stock
Asset logo for symbol RLAY
RLAY53

$4.23

arrow_drop_down2.41%

Performance History

Chart placeholder
Key Stats
Open$4.31
Prev. Close$4.34
EPS-2.61
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$708.02M
PE Ratio-
LOWHIGH
Day Range4.16
4.38
52 Week Range4.11
12.14
Ratios
EPS-2.61

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Relay Therapeutics (RLAY)

Relay Therapeutics Inc (RLAY) is a biotechnology company that specializes in leveraging the power of computation to create new therapies for cancer and other diseases. The company combines insights from protein motion with leading-edge computational tools to design drugs that can target specific proteins and disrupt their function. By targeting proteins that play a crucial role in disease processes, Relay Therapeutics aims to develop innovative treatments that can make a real difference for patients.
With a focus on precision medicine, Relay Therapeutics is at the forefront of a new era in drug discovery. The company's proprietary Dynamo platform allows for the simulation and analysis of protein motion, providing valuable insights into the behavior of key proteins implicated in disease. By understanding how proteins move and interact with other molecules, Relay Therapeutics can identify potential drug targets and design small molecules that can bind to and modulate these targets.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Headquarters
Cambridge
Employees
345
Exchange
NASDAQ
add Relay Therapeutics  to watchlist

Keep an eye on Relay Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Relay Therapeutics 's (RLAY) price per share?

The current price per share for Relay Therapeutics (RLAY) is $4.23. The stock has seen a price change of -$0.1 recently, indicating a -2.42% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Relay Therapeutics (RLAY)?

For Relay Therapeutics (RLAY), the 52-week high is $12.14, which is 187% from the current price. The 52-week low is $4.12, the current price is 2.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Relay Therapeutics (RLAY) a growth stock?

Relay Therapeutics (RLAY) has shown an average price growth of -5.34% over the past three years. It has received a score of 2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Relay Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Relay Therapeutics (RLAY) stock price performance year to date (YTD)?

As of the latest data, Relay Therapeutics (RLAY) has a year-to-date price change of -64.32%. Over the past month, the stock has experienced a price change of -12.96%. Over the last three months, the change has been -43.07%. Over the past six months, the figure is -38.7%.
help

Is Relay Therapeutics (RLAY) a profitable company?

Relay Therapeutics (RLAY) has a net income of -$341.97M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 79.37% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.95K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $25.55M, although specific revenue growth data is currently not available. The gross profit is $20.28M. Operating income is noted at -$373M. Furthermore, the EBITDA is -$389.45M.
help

What is the market capitalization of Relay Therapeutics (RLAY)?

Relay Therapeutics (RLAY) has a market capitalization of $708.03M. The average daily trading volume is 4.22, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level